<DOC>
	<DOC>NCT00807612</DOC>
	<brief_summary>This is a global, multicenter, 2-part, open-label phase 1b and single-arm phase 2 study designed to evaluate the safety and efficacy of AMG 479 in combination with paclitaxel and carboplatin for the first-line treatment of advanced squamous non-small cell lung carcinoma.</brief_summary>
	<brief_title>QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologically or cytologically confirmed advanced squamous NSCLC Measurable disease as defined per modified RECIST criteria ECOG performance status of 0 or 1 ≥18 years old Adequate glycemic function, for subjects with known diabetes Untreated or symptomatic central nervous system (CNS) metastases Prior anticancer therapy as follows: Any prior chemotherapy for squamous NSCLC; Any prior adjuvant or neoadjuvant chemotherapy for squamous NSCLC; Any prior chemoradiation for squamous NSCLC; Central (chest) radiation therapy ≤ 28 days prior to enrollment, radiation therapy for peripheral lesions≤14 days prior to enrollment for squamous NSCLC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AMG 479</keyword>
	<keyword>IGF-1R</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Advanced Squamous Non-Small Cell Lung Cancer</keyword>
	<keyword>antibody 1st-line</keyword>
</DOC>